Mettler-Toledo International Inc. — 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This annual report includes unaudited fourth-quarter results. The company supplies precision instruments and related services globally, including laboratory and industrial instruments, product inspection systems, and retail weighing solutions.
Financial performance and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Net sales | $2.936 billion | $2.725 billion |
| Gross profit / gross margin | $1.684 billion / 57.4% | $1.576 billion / 57.8% |
| Earnings before taxes | $651.9 million | $574.2 million |
| Net earnings | $512.6 million | $376.0 million |
| Diluted EPS | $19.88 | $14.24 |
| Cash provided by operating activities | $565.0 million | $516.3 million |
| Capital expenditures | $142.7 million | $127.4 million |
| Cash and cash equivalents at year-end | $178.1 million | $148.7 million |
| Total debt at year-end | $1.035 billion | $979.8 million |
Sales increased 8% in U.S. dollars and 6% in local currencies. Net earnings rose about 36%; reported effective tax rate fell to 21.4% from 34.5%, substantially reflecting the prior-year Tax Cuts and Jobs Act charge and the lower U.S. federal tax rate. Approximate operating cash flow less capital expenditures was $422 million. The company reported $183.0 million of working capital under its stated definition; current assets were $1.046 billion and current liabilities $734.4 million.
Product gross margin was 60.3%, down from 61.1%; service gross margin was 47.0%, up from 46.1%. SG&A declined to 27.7% of sales from 28.9%, while R&D was 4.8% of sales. Debt was partly offset by cash; management reported approximately $856.6 million of net debt. The $1.1 billion revolving credit facility had $600.7 million available at year-end and matures in 2023.
Fourth-quarter results and material changes
- Fourth-quarter sales were $817.9 million, versus $778.0 million in 2017, an increase of about 5%.
- Fourth-quarter net earnings were $181.2 million, versus $77.0 million; diluted EPS was $7.11 versus $2.93. The comparison reflects the significant effect of tax and other items, so reported earnings growth should not be read as solely underlying operating growth.
- For the full year, laboratory sales increased 11% in U.S. dollars (9% local currency); industrial sales increased 5% (3% local currency); retail sales increased 5% (3% local currency). China external-customer sales grew 16% in U.S. dollars, or 14% in local currencies.
- Gross margin declined 0.4 percentage points year over year. Management cited start-up costs at a new manufacturing facility, product introduction costs, tariffs, and unfavorable mix, partly offset by pricing.
- U.S. Operations segment profit fell 9%, while Chinese Operations segment profit rose 17%. China generated 37% of total segment profit, making its operating contribution material despite geographic diversification.
Outlook, management commentary, and risks
Management planned to continue market-share initiatives, expand service and emerging-market sales, invest in product innovation and field resources, improve pricing and productivity, and pursue bolt-on acquisitions. The filing does not provide a clear numerical 2019 sales or EPS forecast. Management described 2018 global market conditions as favorable but cautioned that conditions could change, particularly amid trade and tariff uncertainty.
- U.S. tariffs on certain imports from China were estimated to add approximately $25 million in annualized cost at a 25% tariff rate; mitigation actions were being evaluated and implemented.
- Foreign exchange is a significant exposure. Management estimated a 1% Swiss franc strengthening against the euro could reduce annual pretax earnings by $1.6–$1.8 million; a 1% renminbi weakening against the U.S. dollar could reduce them by $1.5–$1.7 million.
- China accounted for 18% of sales to external customers and approximately 30% of global production. Risks include market volatility, trade restrictions, and limits or approvals affecting cash conversion and repatriation.
- Other key risks include economic downturns and customer delays in capital spending, competition and margin pressure, supplier or manufacturing disruptions, cybersecurity and system failures, regulatory and tax changes, and the possibility of future environmental liabilities.
- Restructuring charges were $18.4 million, primarily employee-related. Other income included a one-time $18.7 million gain from settling Biotix acquisition contingent consideration and a $3.0 million legal charge. The company also incurred $3.6 million of 2018 tax-reform-related charges; $62 million of aggregate transition-tax and related cash charges were expected to be paid over up to eight years.
- Environmental monitoring and remediation obligations include estimated future compliance costs of about $0.4 million at a New Jersey site. The company said no current legal proceeding was expected to have a material adverse effect.
The board authorized an additional $2.0 billion for share repurchases in November 2018; $2.1 billion remained available at year-end. The company repurchased $475 million of shares during 2018. It expects approximately $15 million of net investment in a new manufacturing facility over the next two years. It also expected to recognize $90–$100 million of lease right-of-use assets and corresponding liabilities on adopting the new lease standard in 2019.
Most important facts for investors to verify
- Whether local-currency growth and margin performance continue, especially in laboratory products and China, and whether Chinese segment profitability remains highly significant.
- Actual tariff costs and the effectiveness and costs of mitigation measures, alongside any changes in trade policy.
- Underlying earnings and cash generation after separating the tax-rate benefit and one-time Biotix settlement gain from recurring performance.
- Debt, cash repatriation, and funding needs given ongoing share repurchases, capital spending, pension contributions, and acquisition activity.
- Progress on the new manufacturing facility, restructuring, and Blue Ocean systems implementation, including related costs and operational risks.
PricewaterhouseCoopers LLP issued an unqualified opinion on the consolidated financial statements and concluded internal control over financial reporting was effective as of December 31, 2018.